Speciality Medicines Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 07-11-2024
- Paid Up Capital ₹ 5.12 Cr
as on 07-11-2024
- Company Age 3 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.27 Cr
as on 07-11-2024
- Revenue -42.48%
(FY 2023)
- Profit 42.06%
(FY 2023)
- Ebitda -98.79%
(FY 2023)
- Net Worth 222.19%
(FY 2023)
- Total Assets 129.32%
(FY 2023)
About Speciality Medicines
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 5.12 Cr.
The company currently has active open charges totaling ₹1.27 Cr.
The Key Managerial Personnel (KMP) at Speciality Medicines Private Limited India is Sumit Goyani as CEO. Sumeet Goyani, Parthkumar Goyani, and Vaishali Patel serve as directors at the Company.
- CIN/LLPIN
U85300GJ2021PTC120022
- Company No.
120022
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Speciality Medicines Private Limited offer?
Speciality Medicines Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Infective Drugs & Medicines, HIV Drugs, Cardiovascular Drugs & Medication, Cardiac Drugs, Common Disease Medicines, Psoriasis Ointment, Immunization & Vaccination Drugs, Vaccines.
Who are the key members and board of directors at Speciality Medicines?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumeet Goyani  | Managing Director | 27-Oct-2021 | Current |
| Parthkumar Goyani | Managing Director | 05-Feb-2021 | Current |
| Sumit Goyani | CEO | 27-Oct-2021 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vaishali Patel | Additional Director | 05-Apr-2024 | Current |
Financial Performance of Speciality Medicines.
Speciality Medicines Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 42.48% decrease. The company also saw a substantial improvement in profitability, with a 42.06% increase in profit. The company's net worth Soared by an impressive increase of 222.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Speciality Medicines?
In 2023, Speciality Medicines had a promoter holding of 97.00% and a public holding of 3.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Spemed Techno Private LimitedActive 6 years 11 monthsSumeet Goyani, Parthkumar Goyani and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Oct 2021 | ₹1.27 Cr | Open |
How Many Employees Work at Speciality Medicines?
Speciality Medicines has a workforce of 17 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Speciality Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Speciality Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
